APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade -
- One dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal of ≥ 6 million hematopoietic stem cells among a contemporary population of multiple myeloma patients -
- Management to hold conference call on Tuesday, September 12, 2023 at 8:00 a.m. U.S. EDT -
The Company will host an investor conference call on September 12, 2023 at 8:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until September 14, 2023; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.
https://finance.yahoo.com/news/biolinerx-announces-fda-approval-aphexda-110000569.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.